These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9100422)

  • 1. Case study: nefazodone for juvenile mood disorders.
    Wilens TE; Spencer TJ; Biederman J; Schleifer D
    J Am Acad Child Adolesc Psychiatry; 1997 Apr; 36(4):481-5. PubMed ID: 9100422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity.
    Sajatovic M; DiGiovanni S; Fuller M; Belton J; DeVega E; Marqua S; Liebling D
    Clin Ther; 1999 Apr; 21(4):733-40. PubMed ID: 10363738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
    Cohn CK; Robinson DS; Roberts DL; Schwiderski UE; O'Brien K; Ieni JR
    J Clin Psychiatry; 1996; 57 Suppl 2():15-8. PubMed ID: 8626358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label trial of nefazodone in high comorbidity panic disorder.
    DeMartinis NA; Schweizer E; Rickels K
    J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder.
    Taylor FB; Prather MR
    Depress Anxiety; 2003; 18(2):83-8. PubMed ID: 12964175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nefazodone for social phobia: a clinical case series.
    Worthington JJ; Zucker BG; Fones CS; Otto MW; Pollack MH
    Depress Anxiety; 1998; 8(3):131-3. PubMed ID: 9836065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms.
    Ciraulo DA; Knapp C; Rotrosen J; Sarid-Segal O; Ciraulo AM; LoCastro J; Greenblatt DJ; Leiderman D
    Addiction; 2005 Mar; 100 Suppl 1():23-31. PubMed ID: 15730347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.
    Zajecka JM
    J Clin Psychiatry; 1996; 57 Suppl 2():10-4. PubMed ID: 8626357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety profile of nefazodone.
    Robinson DS; Roberts DL; Smith JM; Stringfellow JC; Kaplita SB; Seminara JA; Marcus RN
    J Clin Psychiatry; 1996; 57 Suppl 2():31-8. PubMed ID: 8626361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder.
    McRae AL; Brady KT; Mellman TA; Sonne SC; Killeen TK; Timmerman MA; Bayles-Dazet W
    Depress Anxiety; 2004; 19(3):190-6. PubMed ID: 15129422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients.
    Mendels J; Reimherr F; Marcus RN; Roberts DL; Francis RJ; Anton SF
    J Clin Psychiatry; 1995; 56 Suppl 6():30-6. PubMed ID: 7649971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nefazodone in the treatment of severe, melancholic, and recurrent depression.
    Marcus RN; Mendels J
    J Clin Psychiatry; 1996; 57 Suppl 2():19-23. PubMed ID: 8626359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nefazodone: aspects of efficacy.
    Rickels K; Robinson DS; Schweizer E; Marcus RN; Roberts DL
    J Clin Psychiatry; 1995; 56 Suppl 6():43-6. PubMed ID: 7649973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic dose range of nefazodone in the treatment of major depression.
    Robinson DS; Marcus RN; Archibald DG; Hardy SA
    J Clin Psychiatry; 1996; 57 Suppl 2():6-9. PubMed ID: 8626365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of depression--newer pharmacotherapies.
    Mulrow CD; Williams JW; Trivedi M; Chiquette E; Aguilar C; Cornell JE; Badgett R; Noël PH; Lawrence V; Lee S; Luther M; Ramirez G; Richardson WS; Stamm K
    Psychopharmacol Bull; 1998; 34(4):409-795. PubMed ID: 10513454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
    Baldwin DS; Hawley CJ; Abed RT; Maragakis BP; Cox J; Buckingham SA; Pover GH; Ascher A
    J Clin Psychiatry; 1996; 57 Suppl 2():46-52. PubMed ID: 8626363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevalence of depressive disorders in children and adolescents attending primary care. A survey with the Aquitaine Sentinelle Network].
    Mathet F; Martin-Guehl C; Maurice-Tison S; Bouvard MP
    Encephale; 2003; 29(5):391-400. PubMed ID: 14615688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxetine treatment of mood and anxiety disorders in children and adolescents.
    Wagner KD
    Psychopharmacol Bull; 2003; 37 Suppl 1():167-75. PubMed ID: 14566209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open trial of nefazodone in adult patients with generalized anxiety disorder.
    Hedges DW; Reimherr FW; Strong RE; Halls CH; Rust C
    Psychopharmacol Bull; 1996; 32(4):671-6. PubMed ID: 8993090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.